Singapore markets closed

Humanigen, Inc. (HGEN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.3700+0.1600 (+7.24%)
At close: 04:00PM EST
2.3600 -0.01 (-0.42%)
After hours: 07:49PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.2100
Open2.2600
Bid2.3700 x 2200
Ask2.4400 x 1400
Day's range2.1450 - 2.3800
52-week range2.1450 - 29.2000
Volume1,069,242
Avg. volume2,049,549
Market cap140.793M
Beta (5Y monthly)-1.93
PE ratio (TTM)N/A
EPS (TTM)-4.2280
Earnings date08 Mar 2022 - 14 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.13
  • Business Wire

    Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab

    BURLINGAME, Calif., January 18, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced a peer-reviewed publication in the Journal of Medical Economics (https://www.tandfonline.com/doi/full/10.1080/13696998.2022.2030148) citing the clinical and associated health economic benefits of lenzilumab. The publication demonstrated, in all cases, lenzilumab plus SOC

  • Business Wire

    Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

    BURLINGAME, Calif., January 10, 2022--Humanigen, Inc. (Nasdaq:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ today outlined the next steps for the development of its lead candidate, lenzilumab, in the prevention of CAR-T therapy related toxicities including ICANS and CRS in patients with relapsed or refractory Non-Hodgkin lymphoma (rrNHL).

  • Business Wire

    Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved

    BURLINGAME, Calif., January 05, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’, announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study has been achieved. The study, sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, enrolled over 400 patients in the primary analysis population at approxim